Serum T2-High Inflammation Mediators in Eosinophilic COPD DOI Creative Commons
Andrius Januskevicius,

Egle Vasyle,

Airidas Rimkūnas

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(12), P. 1648 - 1648

Published: Dec. 21, 2024

Eosinophils are central inflammatory cells in asthma; however, a portion of patients with chronic obstructive pulmonary disease (COPD) have blood or sputum eosinophilia, condition termed eosinophilic COPD (eCOPD), which may contribute to the progression disease. We hypothesize that inflammation eCOPD is related Type 2 (T2)-high seen asthma and serum mediators might help us identify T2-high choose an appropriate personalized treatment strategy. Thus, we aimed investigate ten levels compare them severe non-allergic (SNEA) patients. included 8 subjects eCOPD, 10 SNEA, 11 healthy (HS) as control group. The concentrations biomarkers samples were analyzed using enzyme-linked immunosorbent assay (ELISA). In this study, found distinguished from SNEA by elevated sIL-5Rα, MET, TRX1, ICTP, IL-4, well decreased eotaxin-1 sFcεRI. Moreover, eotaxin-1, sFcεRI demonstrated high sensitivity specificity potential for Furthermore, IL-5 IL-25 combination IL-4 value identifying conclusion, study highlights while drives both through similar mechanisms, distinct expression its reflects imbalance between T1 T2 pathways A combined analysis aid selecting

Language: Английский

Serum T2-High Inflammation Mediators in Eosinophilic COPD DOI Creative Commons
Andrius Januskevicius,

Egle Vasyle,

Airidas Rimkūnas

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(12), P. 1648 - 1648

Published: Dec. 21, 2024

Eosinophils are central inflammatory cells in asthma; however, a portion of patients with chronic obstructive pulmonary disease (COPD) have blood or sputum eosinophilia, condition termed eosinophilic COPD (eCOPD), which may contribute to the progression disease. We hypothesize that inflammation eCOPD is related Type 2 (T2)-high seen asthma and serum mediators might help us identify T2-high choose an appropriate personalized treatment strategy. Thus, we aimed investigate ten levels compare them severe non-allergic (SNEA) patients. included 8 subjects eCOPD, 10 SNEA, 11 healthy (HS) as control group. The concentrations biomarkers samples were analyzed using enzyme-linked immunosorbent assay (ELISA). In this study, found distinguished from SNEA by elevated sIL-5Rα, MET, TRX1, ICTP, IL-4, well decreased eotaxin-1 sFcεRI. Moreover, eotaxin-1, sFcεRI demonstrated high sensitivity specificity potential for Furthermore, IL-5 IL-25 combination IL-4 value identifying conclusion, study highlights while drives both through similar mechanisms, distinct expression its reflects imbalance between T1 T2 pathways A combined analysis aid selecting

Language: Английский

Citations

0